{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:26:09Z","timestamp":1791440769953,"version":"4.3.3"},"reference-count":32,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2018,1,13]],"date-time":"2018-01-13T00:00:00Z","timestamp":1515801600000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To examine whether lowering plasma glucose concentration with the sodium-glucose transporter-2 inhibitor empagliflozin improves \u03b2-cell function in patients with type 2 diabetes mellitus (T2DM).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with T2DM (N = 15) received empagliflozin (25 mg\/d) for 2 weeks. \u03b2-Cell function was measured with a nine-step hyperglycemic clamp (each step, 40 mg\/dL) before and at 48 hours and at 14 days after initiating empagliflozin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Glucosuria was recorded on days 1 and 14 [mean \u00b1 standard error of the mean (SEM), 101 \u00b1 10 g and 117 \u00b1 11 g, respectively] after initiating empagliflozin, as were reductions in fasting plasma glucose levels (25 \u00b1 6 mg\/dL and 38 \u00b1 8 mg\/dL, respectively; both P &amp;lt; 0.05). After initiating empagliflozin and during the stepped hyperglycemic clamp, the incremental area under the plasma C-peptide concentration curve increased by 48% \u00b1 12% at 48 hours and 61% \u00b1 10% at 14 days (both P &amp;lt; 0.01); glucose infusion rate increased by 15% on day 3 and 16% on day 14, compared with baseline (both P &amp;lt; 0.05); and \u03b2-cell function, measured with the insulin secretion\/insulin resistance index, increased by 73% \u00b1 21% at 48 hours and 112% \u00b1 20% at 14 days (both P &amp;lt; 0.01). \u03b2-cell glucose sensitivity during the hyperglycemic clamp was enhanced by 42% at 14 hours and 54% at 14 days after initiating empagliflozin (both P &amp;lt; 0.01).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Lowering the plasma glucose concentration with empagliflozin in patients with T2DM augmented \u03b2-cell glucose sensitivity and improved \u03b2-cell function.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2017-01838","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T20:27:55Z","timestamp":1515788875000},"page":"1402-1407","source":"Crossref","is-referenced-by-count":98,"title":["Empagliflozin Treatment Is Associated With Improved \u03b2-Cell Function in Type 2 Diabetes Mellitus"],"prefix":"10.1210","volume":"103","author":[{"given":"Hussein","family":"Al Jobori","sequence":"first","affiliation":[{"name":"Texas Diabetes Institute and Diabetes Division, University of Texas Health Science Center at San Antonio, San Antonio, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Daniele","sequence":"first","affiliation":[{"name":"Texas Diabetes Institute and Diabetes Division, University of Texas Health Science Center at San Antonio, San Antonio, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Adams","sequence":"first","affiliation":[{"name":"Texas Diabetes Institute and Diabetes Division, University of Texas Health Science Center at San Antonio, San Antonio, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Cersosimo","sequence":"first","affiliation":[{"name":"Texas Diabetes Institute and Diabetes Division, University of Texas Health Science Center at San Antonio, San Antonio, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Solis-Herrera","sequence":"first","affiliation":[{"name":"Texas Diabetes Institute and Diabetes Division, University of Texas Health Science Center at San Antonio, San Antonio, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis","family":"Triplitt","sequence":"first","affiliation":[{"name":"Texas Diabetes Institute and Diabetes Division, University of Texas Health Science Center at San Antonio, San Antonio, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph A","family":"DeFronzo","sequence":"first","affiliation":[{"name":"Texas Diabetes Institute and Diabetes Division, University of Texas Health Science Center at San Antonio, San Antonio, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Abdul-Ghani","sequence":"first","affiliation":[{"name":"Texas Diabetes Institute and Diabetes Division, University of Texas Health Science Center at San Antonio, San Antonio, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2018,1,12]]},"reference":[{"issue":"4","key":"2020070111335604800_B1","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"DeFronzo","year":"2009","journal-title":"Diabetes"},{"issue":"6","key":"2020070111335604800_B2","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.2337\/dc14-0396","article-title":"\u03b2-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment","volume":"37","author":"Halban","year":"2014","journal-title":"Diabetes Care"},{"key":"2020070111335604800_B3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1463-1326.2009.01115.x","article-title":"Genetic and biochemical pathways of beta-cell failure in type 2 diabetes","volume":"11","author":"Talchai","year":"2009","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"2020070111335604800_B4","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.2337\/diabetes.52.10.2461","article-title":"A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes","volume":"52","author":"Kashyap","year":"2003","journal-title":"Diabetes"},{"issue":"5","key":"2020070111335604800_B5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.numecd.2009.03.018","article-title":"Glucose toxicity: the leading actor in the pathogenesis and clinical history of type 2 diabetes - mechanisms and potentials for treatment","volume":"19","author":"Giaccari","year":"2009","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"4","key":"2020070111335604800_B6","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1172\/JCI113157","article-title":"Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats","volume":"80","author":"Rossetti","year":"1987","journal-title":"J Clin Invest"},{"issue":"2","key":"2020070111335604800_B7","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s00125-008-1201-y","article-title":"Hyperglycaemia but not hyperlipidaemia causes beta cell dysfunction and beta cell loss in the domestic cat","volume":"52","author":"Zini","year":"2009","journal-title":"Diabetologia"},{"issue":"3","key":"2020070111335604800_B8","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2337\/diab.34.3.222","article-title":"The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus","volume":"34","author":"Garvey","year":"1985","journal-title":"Diabetes"},{"issue":"1","key":"2020070111335604800_B9","first-page":"1391","article-title":"Effects of intensive insulin therapy upon pancreatic \u03b2 cell function in patients newly diagnosed with type II diabetes","volume":"8","author":"Wang","year":"2015","journal-title":"Int J Clin Exp Med"},{"issue":"8","key":"2020070111335604800_B10","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.2337\/dc10-2105","article-title":"Short-term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and \u03b2-cell function in subjects with long-term remission","volume":"34","author":"Hu","year":"2011","journal-title":"Diabetes Care"},{"issue":"9626","key":"2020070111335604800_B11","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/S0140-6736(08)60762-X","article-title":"Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial","volume":"371","author":"Weng","year":"2008","journal-title":"Lancet"},{"issue":"11","key":"2020070111335604800_B12","doi-asserted-by":"crossref","first-page":"F889","DOI":"10.1152\/ajprenal.00267.2015","article-title":"Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus","volume":"309","author":"Abdul-Ghani","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"issue":"5","key":"2020070111335604800_B13","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1210\/jc.2014-3472","article-title":"Dapagliflozin lowers plasma glucose concentration and improves \u03b2-cell function","volume":"100","author":"Merovci","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2020070111335604800_B14","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"issue":"3","key":"2020070111335604800_B15","first-page":"E214","article-title":"Glucose clamp technique: a method for quantifying insulin secretion and resistance","volume":"237","author":"DeFronzo","year":"1979","journal-title":"Am J Physiol"},{"issue":"1","key":"2020070111335604800_B16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2337\/diab.32.1.35","article-title":"Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia in man","volume":"32","author":"DeFronzo","year":"1983","journal-title":"Diabetes"},{"key":"2020070111335604800_B17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1365-2362.32.s3.5.x","article-title":"The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes","volume":"32","author":"Bergman","year":"2002","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"2020070111335604800_B18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00125-003-1263-9","article-title":"Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study","volume":"47","author":"Gastaldelli","year":"2004","journal-title":"Diabetologia"},{"issue":"5","key":"2020070111335604800_B19","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.2337\/dc05-2179","article-title":"Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose","volume":"29","author":"Abdul-Ghani","year":"2006","journal-title":"Diabetes Care"},{"issue":"9","key":"2020070111335604800_B20","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.2337\/dc11-0291","article-title":"Effects of exenatide on measures of \u03b2-cell function after 3 years in metformin-treated patients with type 2 diabetes","volume":"34","author":"Bunck","year":"2011","journal-title":"Diabetes Care"},{"issue":"3","key":"2020070111335604800_B21","doi-asserted-by":"crossref","first-page":"E871","DOI":"10.1152\/ajpendo.00551.2006","article-title":"Thiazolidinediones improve beta-cell function in type 2 diabetic patients","volume":"292","author":"Gastaldelli","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"23","key":"2020070111335604800_B22","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"issue":"8","key":"2020070111335604800_B23","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1210\/jc.2004-2460","article-title":"Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes","volume":"90","author":"Mari","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2020070111335604800_B24","doi-asserted-by":"crossref","first-page":"e005442","DOI":"10.1136\/bmjopen-2014-005442","article-title":"Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials","volume":"4","author":"Esposito","year":"2014","journal-title":"BMJ Open"},{"issue":"12","key":"2020070111335604800_B25","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1055\/s-0029-1234042","article-title":"Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-na\u00efve patients with type 2 diabetes","volume":"41","author":"Foley","year":"2009","journal-title":"Horm Metab Res"},{"issue":"8","key":"2020070111335604800_B26","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.2337\/dc14-0024","article-title":"HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin","volume":"37","author":"Ahr\u00e9n","year":"2014","journal-title":"Diabetes Care"},{"issue":"5","key":"2020070111335604800_B27","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00125-014-3196-x","article-title":"Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes","volume":"57","author":"Polidori","year":"2014","journal-title":"Diabetologia"},{"issue":"1","key":"2020070111335604800_B28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1507\/endocrj.EJ14-0335","article-title":"Ameliorated pancreatic \u03b2 cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin","volume":"62","author":"Takahara","year":"2015","journal-title":"Endocr J"},{"issue":"5","key":"2020070111335604800_B29","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1177\/107155769500200507","article-title":"Reciprocal variations in insulin-stimulated glucose uptake and pancreatic insulin secretion in women with normal glucose tolerance","volume":"2","author":"Diamond","year":"1995","journal-title":"J Soc Gynecol Investig"},{"issue":"2","key":"2020070111335604800_B30","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00125-008-1195-5","article-title":"Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes","volume":"52","author":"H\u00f8jberg","year":"2009","journal-title":"Diabetologia"},{"issue":"2","key":"2020070111335604800_B31","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J Clin Invest"},{"issue":"10","key":"2020070111335604800_B32","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1007\/s00125-011-2204-7","article-title":"Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol","volume":"54","author":"Lim","year":"2011","journal-title":"Diabetologia"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/103\/4\/1402\/33452611\/jc.2017-01838.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/103\/4\/1402\/33452611\/jc.2017-01838.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T15:34:26Z","timestamp":1593617666000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/103\/4\/1402\/4801231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,12]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2017-01838","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,4]]},"published":{"date-parts":[[2018,1,12]]}}}